TELA Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated November 13, 2025, details material definitive agreements entered into by TELA Bio, Inc. (TELA), a Delaware corporation. The filing reports the execution of a new senior secured term loan facility and a registered direct offering of equity securities intended to fund general corporate purposes, including research and development and working capital.
Key Financial Metrics and Capital Structure
- Debt Facility: Entered into a Perceptive Term Loan Facility with an aggregate principal amount of up to $70.0 million.
- Initial Funding: An initial loan of $60.0 million is scheduled to fund on November 14, 2025.
- Delayed Draw: An additional $10.0 million is available subject to customary conditions.
- Interest Rate: Applicable margin of 7.85% plus the greater of the Reference Rate or 4.25%.
- Equity Offering: Registered direct offering of 4,189,000 shares of Common Stock at $1.11 per share and 7,523,000 Pre-Funded Warrants at $1.1099 per share.
- Expected Proceeds: Net proceeds from the equity offering are expected to be approximately $11.9 million.
- Warrant Issuance: Issuance of warrants to purchase up to 2,333,333 shares of Common Stock to the lender (Perceptive) with an exercise price of $1.11.
Material Changes Versus Prior Period
- Debt Restructuring: Terminated the existing Credit and Security Agreement with MidCap Financial Trust (dated May 26, 2022) effective upon the funding of the new facility.
- Security Interest: Released MidCap's security interest in company assets and replaced it with a first lien perfected security interest in favor of Perceptive Credit Holdings V, LP covering substantially all existing and after-acquired assets.
- Liquidity Position: The company is required to maintain minimum liquidity of $5.0 million under the new credit agreement.
Guidance, Outlook, and Risks
- Use of Proceeds: Funds from the equity offering will be used for sales and marketing, R&D, general and administrative matters, working capital, and capital expenditures.
- Covenants: The company must maintain specific revenue thresholds and minimum liquidity levels. Negative covenants restrict new indebtedness, liens, mergers, and dividends.
- Conditions Precedent: Closing of the equity offering is contingent on the company receiving no less than $8.5 million in gross proceeds by November 17, 2025.
- Risks: Forward-looking statements regarding the completion of the offering and proceeds are subject to market conditions and other uncertainties. An Event of Default could result in immediate acceleration of all outstanding principal and interest.
Investor Verification Checklist
- Verify the closing of the registered direct offering and the receipt of the required $8.5 million gross proceeds by November 17, 2025.
- Confirm the actual funding date and amount of the $60.0 million Initial Loan from Perceptive.
- Review the full text of the Credit Agreement (Exhibit 10.1) for specific revenue covenant thresholds and definitions of "Liquidity."
- Monitor the dilution impact from the issuance of 2,333,333 lender warrants and the potential exercise of 7,523,000 Pre-Funded Warrants.
- Check for any subsequent filings regarding the prepayment premium schedule (2% to 10%) if the company seeks to refinance early.